HKEX: 6086
Adoption of share incentive scheme
Earlier from Fangzhou
- Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner
- Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum
- Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
- Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability